Michael J. Eck

Overview

Best Publications

• EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

  J. Guillermo Paez;Pasi A. Jänne;Pasi A. Jänne;Jeffrey C. Lee;Sean Tracy

  11859
  Citations

• EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

  Susumu Kobayashi;Titus J. Boggon;Tajhal Dayaram;Pasi A. Jänne

  4723
  Citations

• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  3760
  Citations

• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  Cai-Hong Yun;Kristen E. Mengwasser;Angela V. Toms;Michele S. Woo

  2253
  Citations

• Three-dimensional structure of the tyrosine kinase c-Src

  Wenqing Xu;Stephen C. Harrison;Michael J. Eck

  1897
  Citations

• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  Wenjun Zhou;Dalia Ercan;Liang Chen;Cai-Hong Yun

  1223
  Citations

• Structures of Lung Cancer-Derived Egfr Mutants and Inhibitor Complexes: Mechanism of Activation and Insights Into Differential Inhibitor Sensitivity

  Cai-Hong Yun;Titus J. Boggon;Yiqun Li;Michele S. Woo

  1218
  Citations

• Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

  Zhou Songyang;Zhou Songyang;Kermit L. Carraway;Michael J. Eck;Stephen C. Harrison

  1172
  Citations

• Crystal Structure of the Tyrosine Phosphatase SHP-2

  Peter Hof;Scott Pluskey;Sirano Dhe-Paganon;Michael J Eck

  1118
  Citations

• Crystal structures of c-Src reveal features of its autoinhibitory mechanism.

  Wenqing Xu;Amish Doshi;Ming Lei;Michael J Eck

  1102
  Citations

• Mechanism and Function of Formins in the Control of Actin Assembly

  Bruce L. Goode;Michael J. Eck

  1030
  Citations

• Structure and regulation of Src family kinases.

  Titus J Boggon;Michael J Eck

  897
  Citations

• The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.

  M J Eck;S R Sprang

  875
  Citations

• Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

  Yong Jia;Cai-Hong Yun;Eunyoung Park;Dalia Ercan

  828
  Citations

• Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck

  Michael J. Eck;Steven E. Shoelson;Stephen C. Harrison;Stephen C. Harrison

  700
  Citations

• A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

  Takaaki Sasaki;Jussi Koivunen;Atsuko Ogino;Masahiko Yanagita

  699
  Citations

• Structure of PAK1 in an Autoinhibited Conformation Reveals a Multistage Activation Switch

  Ming Lei;Wange Lu;Wuyi Meng;Maria-Carla Parrini

  679
  Citations

• Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

  Andrew L. Kung;Sonya D. Zabludoff;Sonya D. Zabludoff;Steven J. Freedman;Steven J. Freedman

  631
  Citations

• Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.

  Steven J. Freedman;Zhen-Yu J. Sun;Florence Poy;Andrew L. Kung

  615
  Citations

• Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

  Peter S. Hammerman;Martin L. Sos;Alex H. Ramos;Chunxiao Xu

  593
  Citations